New head of worldwide development for GlaxoSmithKline

London, UK — February 6, 2003 — GlaxoSmithKline announced the appointment of Ronald Krall, MD, as senior vice president, Worldwide Development, Research & Development, effective February 19. Krall will have global responsibility at GSK for clinical development, medical affairs and regulatory affairs.

“Dr Krall brings to GSK broad scientific and clinical knowledge, international experience, and a strong record in pharmaceutical R&D,” says Tadataka Yamada, MD, chairman, GSK R&D. “He shares our sense of urgency about creating innovative medicines for patients in need.”

Krall holds a BA degree in mathematics from Swarthmore College and an MD degree from the University of Pittsburgh and is board-certified in neurology. He has led drug-development programs in numerous therapeutic areas during his two decades in the pharmaceutical industry. Since 1992, he has worked in senior R&D management positions at AstraZeneca and one of its predecessor companies, including roles in which he headed global clinical development. Most recently, he was senior vice president, US Drug Development, at AstraZeneca, with responsibility for all US clinical and regulatory activities.